When embarking on a clinical trial of an investigational medicinal product (IMP) for the first time in humans, the risks associated with the administration of the compound must be identified and mitigated accordingly. This article outlines some of the guidance sponsors should consider when designing a first-in-human trial. The procedures in the UK for trials using higher risk compounds and MHRA accreditation of Phase 1 units is also discussed.
Get full access to this article
View all access options for this article.
References
1.
The Medicines for Human Use (Clinical Trials) Regulations. May 2004. SI 2004, No. 1031. Amendments: Aug 2006. SI 2006, No. 1928 and Dec 2006. SI 2006, No 2984
2.
3.
4.
5.
6.
7.
8.
9.
Expert scientific group on phase 1 clinical trials. London: The Stationery Office, 2006
10.
SibilleM, DonazzoloY, LecozF, KrupkaE. After the London tragedy, is it still possible to consider Phase I is safe. Br J Clin Pharmacol2006; 62: 502–3
